Page last updated: 2024-08-26

wr 1065 and Cholangiocarcinoma

wr 1065 has been researched along with Cholangiocarcinoma in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Ben-Josef, E; Chen, J; Ensminger, W; Feng, M; Feng, MR; Knol, JA; Lawrence, TS; Lu, Z; Normolle, DP; Pan, CC; Smith, DE	1

Trials

1 trial(s) available for wr 1065 and Cholangiocarcinoma

Article	Year
A phase I clinical and pharmacology study using amifostine as a radioprotector in dose-escalated whole liver radiation therapy. International journal of radiation oncology, biology, physics, 2012, Aug-01, Volume: 83, Issue:5 Topics: Adult; Aged; Amifostine; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Carcinoma, Hepatocellular; Cholangiocarcinoma; Female; Humans; Liver; Liver Neoplasms; Logistic Models; Male; Maximum Tolerated Dose; Mercaptoethylamines; Middle Aged; Organs at Risk; Prospective Studies; Radiation Dosage; Radiation Injuries; Radiation Tolerance; Radiation-Protective Agents; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Conformal	2012

Article

Year

A phase I clinical and pharmacology study using amifostine as a radioprotector in dose-escalated whole liver radiation therapy.

International journal of radiation oncology, biology, physics, 2012, Aug-01, Volume: 83, Issue:5

Topics: Adult; Aged; Amifostine; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Carcinoma, Hepatocellular; Cholangiocarcinoma; Female; Humans; Liver; Liver Neoplasms; Logistic Models; Male; Maximum Tolerated Dose; Mercaptoethylamines; Middle Aged; Organs at Risk; Prospective Studies; Radiation Dosage; Radiation Injuries; Radiation Tolerance; Radiation-Protective Agents; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Conformal

2012